ZIMHI is a high-dose naloxone injection product candidate intended for the treatment of opioid overdose. Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate ...
It’s an unusual day for Adamis Pharmaceuticals (NASDAQ:ADMP) stock traders, to say the least. That’s because the company recently announced its intent to acquire DMK Pharmaceuticals. Adamis’ ...
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (ADMP) (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering ...
Adamis Pharmaceuticals, a developer of treatments for allergic reactions, opioid overdoses and respiratory ailments, has sidestepped a nasty proxy fight with a disgruntled shareholder — at least for ...
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), has ...
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product ...
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) shares are trading higher today, and the stock began trading on the REG SHO Threshold Security List. Monday, the company, in an SEC filing, said it ...
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid ...
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results